Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Baghdad
About this trial
The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).
The main questions it aims to answer are:
Does vision improve on the eye chart after the injection?
Does the injection lower retinal swelling (reduction in thickness) within 3 months?
Participants will:
Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).
Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.
Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.
Contact the clinic if they notice pain, redness, new floaters, or worsening vision.
Eligibility criteria
Qualifiers
Non-infectious uveitis complicated with macular edema
Uveitic macular edema of less than four months' duration
Macular edema persisted despite lack of intra-ocular inflammation
No response to posterior sub-Tenon triamcinolone acetonide injections
Disqualifiers
Those with epiretinal membrane-associated macular edema
Below 18 years
Trial design
Treatments tested in this trial
- Suprachoroidal triamcinolone acetonide injection
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov